- Rucaparib Camsylate
-
- $0.00 / 1g
-
2026-05-20
- CAS:1859053-21-6
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Rucaparib Camsylate
-
- $5.00/ KG
-
2026-04-10
- CAS:1859053-21-6
- Min. Order: 1KG
- Purity: 99% hplc
- Supply Ability: 500TONS
|
| | Rucaparib Camsylate Basic information |
| Product Name: | Rucaparib Camsylate | | Synonyms: | Rucaparib Camsylate;8‐Fluoro‐2‐(4‐methylaminomethyl‐phenyl)‐1,3,4,5‐tetrahydro‐azepino[5,4,3‐cd] indol‐6‐one (S)‐camphorsulfonate Salt;Rucaparib Camphosulfonate;Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with 8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2-ef][2]benzazepin-6-one (1:1);8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H- azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo [2.2.1] hept-1-yl) methanesulfonic acid salt;Rucaparib monocamsylate;8-Fluoro-5-(4-((methylamino)methyl)phenyl)-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-1-one ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate;Asciminib Impurity 1 | | CAS: | 1859053-21-6 | | MF: | C29H34FN3O5S | | MW: | 555.67 | | EINECS: | | | Product Categories: | api | | Mol File: | 1859053-21-6.mol |  |
| | Rucaparib Camsylate Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO:79.63(Max Conc. mg/mL);143.31(Max Conc. mM) | | form | Solid | | color | Light yellow to gray | | InChIKey | INBJJAFXHQQSRW-STOWLHSFSA-N | | SMILES | FC1=CC(C(NCC2)=O)=C3C2=C(C4=CC=C(CNC)C=C4)NC3=C1.CC5(C)[C@@H]6CC[C@@]5(CS(O)(=O)=O)C(C6)=O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Repr. 2 |
| | Rucaparib Camsylate Usage And Synthesis |
| Uses | Rucaparib Camsylate is a novel DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1) inhibitor. | | Definition | ChEBI: Rucaparib camsylate is a camphorsulfonate salt obtained by reaction of rucaparib with one molar equivalent of (1S,4R)-camphorsulfonic acid. It is an inhibitor of poly (ADP-ribose) polymerase and is used as monotherapy for advanced ovarian cancer and deleterious germline or somatic BRCA mutation. It has a role as an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor. It is a camphorsulfonate salt and an azepinoindole. It contains a (S)-camphorsulfonate and a rucaparib(1+). | | Biological Activity | Rucaparib is an inhibitor of the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). It has been found to have anticancer activity in a number of cancers and has been approved for treatment of previously treated, BRCA-mutant ovarian cancer. | | in vivo | Rucaparib (AG014699) monocamsylate and AG14584 significantly increase Temozolomide toxicity. Rucaparib (1 mg/kg) monocamsylate significantly increases Temozolomide-induced body weight loss. Rucaparib (0.1 mg/kg) monocamsylate results in a 50% increase in the temozolomide-induced tumor growth delay[1].
Rucaparib (10 mg/kg for i.p. or 50, 150 mg/kg for p.o.; daily for 5 days per week for 6 weeks) monocamsylate significantly inhibits the growth of the tumor, and there is one complete tumor regression and two persistent partial regressions[2].
Rucaparib (150 mg/kg; p.o.; once per week for 6 weeks or three times per week for 6 weeks) monocamsylate has greatest antitumor effect with three complete regressions[2].
Rucaparib monocamsylate enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts[6].
| Animal Model: | Female CD-1 nude mice aged 10-12 weeks with Capan-1 cells[2] | | Dosage: | 10mg/kg or 50, 150 mg/kg | | Administration: | 10mg/kg for i.p. or 50, 150 mg/kg for p.o. | | Result: | Significantly inhibited the growth of the tumor.
|
| | IC 50 | PARP-1: 1.4 nM (Ki); PARP-2; PARP-3 | | storage | Store at -20°C |
| | Rucaparib Camsylate Preparation Products And Raw materials |
|